Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 8/20 | 0.52 |
| ▸ | NPY4R | P50391 | 8/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.52 |
| ▸ | NPY1R | P25929 | 6/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.49 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.46 |
| ▸ | CALCR | P30988 | 5/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30996221 | 0.98 | NPY2R (0.53) | NPY2RNPY4RNPY5RNPY1REPHA2 | |
| SCHEMBL29679064 | 0.93 | NPY2R (0.49) | NPY2RNPY4RNPY5RNPY1REPHA2 | |
| SCHEMBL29679071 | 0.93 | NPY2R (0.49) | NPY2RNPY4RNPY5RNPY1REPHA2 | |
| SCHEMBL29743132 | 0.90 | EPHA2 (0.50) | NPY2RNPY4RNPY5RNPY1REPHA2 | |
| SCHEMBL29743133 | 0.88 | EPHA2 (0.48) | NPY2RNPY4RNPY5RNPY1REPHA2 | |
| SCHEMBL29659402 | 0.88 | EPHA2 (0.48) | NPY2RNPY4RNPY5RNPY1REPHA2 | |
| SCHEMBL29743135 | 0.87 | EPHA2 (0.46) | NPY2RNPY4RNPY5RNPY1REPHA2 | |
| SCHEMBL30495689 | 0.86 | NPY2R (0.57) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL31214775 | 0.85 | NPY2R (0.46) | NPY2RNPY4RNPY5RNPY1REPHA2 | |
| SCHEMBL30712901 | 0.85 | NPY2R (0.61) | NPY2RNPY4RNPY5RNPY1RRAMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932872-B2 | Dual chimeric antigen receptor-t cell which can be regulated, construction method therefor and use thereof | NANJING ANJI BIOLOGICAL TECHNOLOGY CO., LTD (CN) | 2024-03-19 | — | — | US | claimed |
| US-20220202912-A1 | Polypeptides in Preparation of Drugs for Treatment or Prevention of Rheumatoid Arthritis | XU HANMEI (CN) | 2022-06-30 | — | — | US | claimed |
| CN-109879969-B | HM-3 fusion protein and application thereof | 天士力生物医药股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11932872-B2 | Dual chimeric antigen receptor-t cell which can be regulated, construction method therefor and use thereof | NANJING ANJI BIOLOGICAL TECHNOLOGY CO., LTD (CN) | 2024-03-19 | — | — | US | disclosed |
| US-11655308-B2 | HM-3 fusion protein and application thereof | TASLY BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20220202912-A1 | Polypeptides in Preparation of Drugs for Treatment or Prevention of Rheumatoid Arthritis | XU HANMEI (CN) | 2022-06-30 | — | — | US | disclosed |
| US-20220202912-A1 | Polypeptides in Preparation of Drugs for Treatment or Prevention of Rheumatoid Arthritis | XU HANMEI (CN) | 2022-06-30 | — | — | US | disclosed |
| CN-111995686-B | Medicine with anti-angiogenesis activity and preparation method thereof | 兰州大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-114560947-A | Fusion protein for inhibiting angiogenesis | 兰州大学 | 2022-05-31 | — | — | CN | disclosed |
| EP-3722305-A9 | HM-3 FUSION PROTEIN AND USE THEREOF | Tasly Biopharmaceuticals Co., Ltd. (CN) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202912-A1 | Polypeptides in Preparation of Drugs for Treatment or Prevention of Rheumatoid Arthritis | ITGA2, ITGB3, ITGAV | NPY2R 340/4885NPY4R 687/4885NPY5R 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.